In the end everybody, no matter what PPHM or PPHM BoD related emotions, anger or fear they express, goes for there investment and the return on investment.
The MEANINGFUL return is in PS-Targeting, that is what they invested in. Now comes a guy and he says STOP research, monetise IP and Pipelines and put everything in Avid. So I thing that long long will go for a solution that gives them PPHM (minus those they blame for things not going sufficiently fast and smooth, which are ES, DP and CJ), including 1 old (King) and 3 new (LIAS + 2) BoD members and 3 RONIN.
Everyone knows that KING is pro-AVID (it is kind of his baby). So the 3 RONIN will have all needed support (3+1)=majority. And LIAS is the director of Avid, I can't believe he would not support BoD propositions for the good of Avid. So with 3 RONON, KING and LIAS the Avid plans are a FACT. And that is ALL RONIN claims to want, extend AVID, well in 4 PPHM and 3 RONIN without ES, CJ and DP it is exactly what they get.
As for PS-Targeting, that is still the core leverage item (IP+Pipelines). I only fear that all the campaiging trying to tell us that a failed clinical trial is the same as a failed study (which has been proven by MANY BP and MANY BLOCKBUSTER drugs that it is NOT the same) is the same thing. Hence those that less understand Bavituximab's performance APPART from the control arm may think it is not working and it is my believe that is EXACTLY what they want us to think, so it can be monetised for breadcrumbs. But remeber what Memorial Sloan Kettering Dr. Wlchok said about it in the conference that north attended: All research point in the direction that PS-targeting will be needed to create a tumor environment in which the IO drugs (e.g. opdivo, Keytruda, etc) can increase there foot print. Dr. Brekken said 100 to 200%. And remeber the recent CAR-T presentation by Wolchok related to combining it with PS targeting and the resulting toxic benefits which are the LARGEST obstacle for CAR-T at this moment.
That is the trued and verifiable and that is where the value is. RONIN move at this point just comes where the scientific society and the drug market is waking up on that subject, so it is NOW one need to HI-JACK it or it is going to become EXTREMELY EXPENSIVE.
You are all looking at an attempt to do so. I expect a LARGE number of BROKER NON-VOTES (because I suspect a BP pile of non-voting PPHM shares) and hence a larger wait for RONIN and Dart votes because broker non-votes DO NOT COUNT for BoD voting, only to establish quorum. Hence the bigger chance for RONIN to get his candidates in and the opportunity for US to unbalance the vote because in that scenario OUR VOTES FINALLY MEAN SOMETHING.
Market Data 
Markets 
AI
